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A total of 18 composite tissue allotransplants of the face have currently been reported. Prior to the start of
the face transplant programme, there had been intense debate over the risks and beneﬁts of performing
this experimental surgery. This review examines the surgical, functional and aesthetic, immunological
and psychological outcomes of facial transplantation thus far, based on the predicted risks outlined in
early publications from teams around the world.
The initial experience has demonstrated that facial transplantation is surgically feasible. Functional
and aesthetic outcomes have been very encouraging with good motor and sensory recovery and
improvements to important facial functions observed. Episodes of acute rejection have been common, as
predicted, but easily controlled with increases in systemic immunosuppression. Psychological
improvements have been remarkable and have resulted in the reintegration of patients into the outside
world, social networks and even the workplace. Complications of immunosuppression and patient
mortality have been observed in the initial series. These have highlighted rigorous patient selection as
the key predictor of success.
The overall early outcomes of the face transplant programme have been generally more positive than
many predicted. This initial success is testament to the robust approach of teams. Dissemination of
outcomes and ongoing reﬁnement of the process may allow facial transplantation to eventually become
a ﬁrst-line reconstructive option for those with extensive facial disﬁgurements.
 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The world’s ﬁrst allotransplant of a human face was success-
fully performed in Amiens, France in November 2005.1 This
signalled the emergence of a new reconstructive option for those
with extensive facial disﬁgurements. Composite tissue allo-
transplantation of the face is currently in its experimental phase,
with a total of 18 procedures reported to date (Table 1). Following
the early positive experience observed in hand transplantation
and encouraging experimental evidence there was optimism that
facial transplantation could be successfully performed by the late
1990s. Subsequently the technical, immunological, ethical,
psychological and legal aspects of the procedure were heavily
debated. The Royal College of Surgeons of England produced
working party reports in 20032 and 20063 and teams throughout
the world made contributions to the medical literature,
addressing the risks and beneﬁts of facial transplantation.4e12
This paper uses the challenges highlighted in these early papers591; fax: þ44 207 830 2195.
ial.ac.uk (K. Shanmugarajah),
ciates Ltd. Published by Elsevier Ltto examine the surgical, functional and aesthetic, immunological
and psychological outcomes of the face transplant programme
so far.2. Surgical outcomes
Prior to the ﬁrst case in Amiens, there were varied opinions on
the surgical challenge of facial transplantation, with some teams
suggesting that the procedure would be no more difﬁcult than
conventional reconstructive techniques10 and others raising
signiﬁcant concerns.4 However, surgical feasibility of facial trans-
plantation was predicted, based on the success of microsurgical
techniques.2,3,8 Failure of vascular anastomoses was identiﬁed as
a potential risk that could result in removal of the transplanted
tissue, rendering the recipient at the bottom of the reconstructive
ladder.2e5 Thus far, facial allografts have varied in extents of skin,
muscle and bone harvested (Table 1), but all have been grafted
successfully and remained viable following surgery. Post-operative
venous thrombosis has been reported by the Barcelona team,
requiring reanastomosis on post-operative day three.13 There have
been no further concerns over the vascular anastomosis in this
patient.d. All rights reserved.
Table 1
Overview of face transplants performed to date.
Team
(Surgeon)
Date Location Recipient
(age/gender)
Mechanism of
injury
Donor Allograft Current
Status
Devauchelle/
Dubernard
(1)
Nov 2005 Amiens,
France
38, F Dog bite Brain dead,
heart-beating
Peri-oral muscles, oral and nasal mucosa,
nose, bilateral facial vessels, zygomatic,
buccal and mandibular facial nerve branches,
infra-orbital and mental nerves
Alive
Guo Apr 2006 Xi’an, China 30, M Bear attack Non heart-beating Parotid gland, partial buccal mucosa,
partial masseter, partial zygomatic
arch, lateral and infra-orbital walls,
maxillary sinus, upper lip, nose, nasal bone
Died at
27 mo
Lantieri (1) Jan 2007 Paris,
France
29, M Plexiform
neuroﬁbroma
Brain dead,
heart-beating
Bilateral parotids, nose, oral mucosa, facial,
mental and infra-orbital nerves, bilateral
external carotid arteries, thyrolinguofacial
veins
Alive
Siemionow Dec 2008 Cleveland,
USA
45, F Shotgun injury Brain dead,
heart-beating
Total nose, lower eyelids, upper lip, total
infra-orbital ﬂoor, bilateral zygomas, anterior
maxilla with alveolus, anterior hard palate,
bilateral parotids, bilateral facial arteries,
external jugular veins, left posterior facial
vein bilateral facial nerves
Alive
Lantieri (2) Mar 2009 Paris,
France
27, M Shotgun injury Brain dead,
heart-beating
Parotid glands, masseter, oral mucosa,
upper and lower lips, chin, nose,
premaxilla, bilateral anterior maxillary
sinus wall, external carotid artery,
external jugular vein, thyrolinguofacial
trunk, facial nerve, supra- and infra-orbital
nerves
Alive
Lantieri (3) Apr 2009 Paris,
France
37, M Burns Brain dead,
heart-beating
Scalp, ears, bilateral parotids, masseter,
oral mucosa, upper and lower lips, external
carotid artery, external jugular vein,
thyrolinguofacial trunk, facial nerve,
mental and infra-orbital nerves
Died at
2 mo
Pomahac (1) Apr 2009 Boston,
USA
59, M Electrical injury Brain dead,
heart-beating
Facial mimetic muscles, upper lip, nose,
maxilla and hard palate, oral mucosa,
bilateral facial arteries, left facial vein,
right external jugular vein, facial nerve,
infra-orbital nerve
Alive
Cavadas Aug 2009 Valencia,
Spain
42, M Radiotherapy damage Brain dead,
non-heart beating
Skin from oral commissures to earlobes
and down to upper neck, mandible from
right angle to left condyle, tongue, ﬂoor
of mouth, hyoid bone, suprahyid muscles,
six salivary glands, right lingual and facial
arteries, left internal maxillary, lingual
and facial arteries, bilateral common
and internal carotid arteries, bilateral
external jugular, thyrolingual and
internal jugular veins.
Alive
Lantieri (4) Aug 2009 Paris,
France
33, M Shotgun injury Brain dead
heart-beating
Lower two thirds of nose, mouth,
maxilla, jaw skin and oral mucosa
Alive
Devauchelle/
Dubernard
(2)
Nov 2009 Amiens.
France
27, M Pyrotechnic
explosion
Brain dead,
heart-beating
Maxilla, mandible lower lip, ﬂoor
of mouth and chin
Alive
Gomez Cia Jan 2010 Seville,
Spain
35, M Neuroﬁbromatosis Non-heart beating Lips, oral mucosa, perioral muscles,
bilateral cheeks, bilateral parotid
glands, bilateral facial nerves, bilateral
mental nerves, bilateral infra-orbital
nerves, bilateral common carotid arteries,
bilateral jugular veins, osseous chin segment
Alive
Barret Mar 2010 Barcelona,
Spain
31, M Shotgun injury Brain dead
heart-beating
Facial skin and muscles, eyelids, lacrimal
ducts, hard palate, ﬂoor of mouth, upper
and lower lips, cheek mucosa, mandible,
maxilla, two thirds of zygoma, nose, external
carotid arteries, external jugular veins,
supraorbital, infra-orbital, mandibular
nerves and frontal, buccal and zygomatic
branches of facial nerve
Alive
Lantieri (5) Jun 2010 Paris, France 35, M Neuroﬁbromatosis Not reported Not yet reported Alive
(continued on next page)
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Table 1 (continued )
Team
(Surgeon)
Date Location Recipient
(age/gender)
Mechanism of
injury
Donor Allograft Current
Status
Pomahac (2) Mar 2011 Boston, USA 25, M Electrical injury Not reported Nose, lips, facial skin and muscles
of facial animation
Alive
Pomahac (3) April 2011 Boston, USA 30, M Electrical injury Not reported Forehead, nose, lips, facial skin,
muscles of facial animation
Alive
Lantieri (6) April 2011 Paris, France M Shotgun injury Not reported Not reported Alive
Lantieri (7) April 2011 Paris, France M Shotgun injury Not reported Not reported Alive
Pomahac (4) May 2011 Boston, USA 57, F Chimpanzee attack Not reported Forehead, nose, lips, facial skin, muscles
of facial animation, left hand
and partial right hand
Alive
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REVIEWThe experimental and clinical experience of facial trans-
plantation has allayed early concerns that allografts containing the
craniofacial skeleton would not be viable if just supplied by the
facial artery.7 It was suggested that such allografts would require
a branch of the maxillary artery to be raised,14 increasing the
difﬁculty of the retrieval process. However, Pomahac et al have
shown in preclinical cadaveric dissections that numerous small
arterial connections exist between the deep branches of the facial
artery and the distal branches of the maxillary artery.15 Conse-
quently, the maxilla and hard palate of a facial allograft can receive
an adequate blood supply from the facial artery alone. Subsequent
to these studies, they successfully transplanted a midfacial allo-
graft, including maxilla and zygoma based on the facial artery.15
Furthermore, the fourth face transplant, also performed in the
United States, containing maxilla and palate received its vascular
perfusion from just the facial artery.16 Despite initial fears over the
revascularisation of extensive facial allografts,4 the Barcelona group
have reported patency of a ﬂap containing the entire face on
a single external carotid artery.13 It, therefore, appears that
adequate reperfusion of facial allografts can be achieved with
relatively few vascular anastomoses.
Whilst all facial allografts have been successfully transplanted,
some teams have described extensive intra-operative blood loss.
The ﬂap for the second procedurewas procured quickly from a non-
heart beating donor, with no measures taken for haemostasis,
resulting in 5 L of blood loss from around the recipient wound.17
Lantieri et al have described transfusion requirements of 10 or
more units of packed red blood cells in each of their ﬁrst four
recipients.18 Substantial blood loss also occurred in the second
Spanish transplant, requiring transfusion of 24 units of packed red
blood cells and resulting in a post-transplant dilutional coagulop-
athy.19 Interestingly, this patient also developed post-transplant
rhabdomyolysis, attributed to the long period of intra-operative
immobilisation and extensive blood loss.20
3. Functional and aesthetic outcomes
Return of normal function in transplanted facial musculature
and nerves were considered unlikely outcomes before the ﬁrst
procedure. Thus far, quick sensory recovery has been consistently
described in face transplants with available follow-up reports
(Table 2).13,17,18,21e24 Lantieri et al have described thermal and
mechanical sensory reinnervation occurring as quickly as three
months post-surgery in the third recipient.21 In addition, Duber-
nard et al reported that the entire skin surface and oral mucosa of
the ﬁrst allograft was sensate by the fourteenth post-operative
week,1 with complete sensory recovery to light touch, heat and
cold achieved by six months.22 Similarly, Pomahac et al have
described sensory recovery, in their ﬁrst patient, to light touch, heat
and cold, pinprick and two point discriminaton to 15 mm by sixmonths.24 The third Spanish recipient, who received a facial graft
containing the entire face, had regained total restoration of
sensation in forehead, eyelids, cheeks and oral mucosa by four
months.13 Such complete recovery has exceeded initial
expectations.7
The working party reports of the Royal College of Surgeons of
England mentioned the use of facial slings to aid function in the
event of poor motor recovery. This has not been reported so far. As
predicted, restoration of motor function has been generally slower
than sensory recovery (Table 2). However, Lantieri et al have
demonstrated initial motor recovery as early as two months post-
transplant, with complete mouth closure achieved by eight
months in the ﬁfth recipient.21
As foreseen in the working party reports functional outcomes of
facial transplantation have been favourable.3 Even with unsatis-
factory facial nerve anastomosis in the Chinese transplant, the
patient was still able to eat, drink and talk normally at two years.17
Siemionow et al described signiﬁcant functional recovery by eight
months post-transplant, including restoration of smell, ability to
eat solid foods, drink from a cup and speak, even in the absence of
nerve coaption.16 Importantly, there was reduction of chronic pain
levels from scarred and contracted tissues, from 8/10 before the
transplant to 1/10 afterwards.23 In the follow-up report of their ﬁrst
four recipients, Lantieri et al have described recovery of intelligible
speech in all patients between days 10 and 24 post-operatively.18
Signiﬁcant functional improvements, including oral intake and
the ability to breath and smell were established almost immedi-
ately following surgery in the seventh recipient.24 Interestingly,
there have been ongoing functional improvements in the ﬁrst
recipient of a facial allograft at ﬁve years post-transplant. This
patient is now able to chew, swallow, eat, smile, speak, drink and
blow.25
From an aesthetic perspective, computer simulation modelling
of change in appearance after facial transplantation had predicted
that recipient appearance would be derived as a composite face12
and this has been the observed clinical outcome.26 The recipient
of the ﬁrst face transplant has reported that she is very satisﬁed
with the result.22 Siemionow et al have described their patient as
reacting favourably post-transplantation, with a positive self-
appearance rating of 5/10 at three weeks (her pre-transplant
rating was also 5/10) and 8/10 at ﬁve months.23 Furthermore,
Pomahac et al have assessed the aesthetic outcome of their patient
to be excellent at one year.24
Face transplant teams that have published follow-up reports
thus far have described attempts to match recipients with donors of
matched age, sex and skin phenotype.1,17,18,26 Due to restrictions on
face donors, Lanieri et al have described an age discrepancy in their
ﬁrst four transplants, performed in Paris, where donors were on
average 24 years older than recipients.18 The donor for their ﬁrst
case was 36 years older than the recipient. Computer simulation
Table 2
Sensory, motor, functional, aesthetic and psychological outcomes of facial transplantation.
Team Sensory Recovery Motor Recovery Functional Recovery Aesthetic Outcome Psychological Outcome
Devauchelle/
Dubernard (1)
Light touch e 14wks
Heat/cold e 6 mo
Lip occlusion - 6 mo
Chin/nose muscle
contractions-12 mo
Mobilise food bolus e 6 mo
Symmetrical smile e 18 mo
Pt very satisﬁed at 18 mo Social re-integration-12wks
Guo Light touch e 3 mo
Heat/cold e 8 mo
Poor function e levator
labii superioris,
levator anguli oris,
Unable to smile
symmetrically e 2yrs
Able to eat, drink, talk
Reported as improved
Further excision of redundant
tissues (7 mo, 12 mo)
Accepted new face easily
Lantieri (1) Light touch e 3 mo
Heat/cold e 3 mo
Motor recovery, seen
by EMG, at 12 mo
Not reported Reduced concern about
appearance post-op
Objective improvement in
quality of life and appearance.
Began job at 13 mo
Siemionow Light touch e 6 mo
Heat/cold e
not reported
Progressive motor
recovery at 8 mo
Able to eat and drink,
speak, smell.
Reduced chronic pain levels
(8/10 pre-transplant, 1/10
post-transplant)
Self-appearance rating 3/10
pre-transplant, 7e8/10
post-transplant.
Objective improvement in
depression, body image
and quality of life. Anxiety
and self-esteem levels
remained constant
Lantieri (2) Light touch e partial
deep pressure
sensitivity at 8 mo
Heat/cold e
absent at 17 mo
Recovery of orbicularis
oris e 3 mo
(right), 2 mo (left).
Complete mouth
closure e 8 mo
Objective improvement in
appearance
Objective improvement in
quality of life. Return to
employment at 18 mo
Lantieri (3) Not yet reported Not yet reported Not yet reported Objective improvement in
appearance
Objective improvement in
quality of life
Pomahac (1) Light touch e 6 mo
Heat/cold e 6 mo
Progressive recovery
over 12 mo
Symmetrical smile with
2e3 cm excursion
of corners of mouth
at 12 mo
Motor control of
transplanted
upper lip at 12 mo
Speech and ability
to breath and
smell improved
immediately
post-op
Ability for oral intake by 3d
Unable to pucker lips at 12 mo
Assessed as excellent at
12 mo by team.
Accepted new face.
No psychiatric events
at 12 mo.
Enhanced social
capacity by 5 wks
Cavadas Not yet reported Not yet reported Mandible excursion
10 mm at 16 mo
Swallowing and starting
phonation at 16 mo
Not yet reported Not yet reported
Lantieri (4) Light touch e
absent at 12 mo
Heat/cold -
absent at 12 mo
Recovery of left zygomatic
muscle e 5 mo
Recovery of orbicularis
oris e absent at
12 mo (right), 5 mo (left)
Complete mouth
closure e 12 mo
Objective improvement
in appearance
Objective improvement in
quality of life
Devauchelle/
Dubernard
(2)
Not yet reported Not yet reported Not yet reported Pt satisﬁed at 20 mo Not yet reported
Gomez Cia Not yet reported Not yet reported Not yet reported Not yet reported Not yet reported
Barret Recovery of total
sensation
in forehead,
eyelids, cheeks
intraoral
mucosa at 4 mo.
No sensory recovery
in lips at 4 mo.
Active movement frontalis,
lateral zygomatic
muscles, upper orbicularis
oculii at 4 mo.
EMG showed motor
reinnervation at
commissures of mouth
at 120d
Unrestricted mastocatory
movement at 4 mo.
Unable to close eyes
fully at 4 mo
Pt satisﬁed at 4mo. No psychological
probs at 4mo.
Lantieiri (5) Not yet reported Not yet reported Not yet reported Not yet reported Not yet reported
Pomahac (2) Not yet reported Not yet reported Not yet reported Not yet reported Not yet reported
Pomahac (3) Not yet reported Not yet reported Not yet reported Not yet reported Not yet reported
Lantieri (6) Not yet reported Not yet reported Not yet reported Not yet reported Not yet reported
Lantieri (7) Not yet reported Not yet reported Not yet reported Not yet reported Not yet reported
Pomahac (4) Not yet reported Not yet reported Not yet reported Not yet reported Not yet reported
Abbreviation: EMG e electromyography.
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below and 10 years above the recipient’s age.27 Skin mismatching
or premature aging of the allograft have not been reported for
patients thus far, but longer follow-up is required. The transfer ofrosacea between donor and recipient28 was observed in the
seventh face transplant, identifying dermatological conditions of
donors as additional selection criteria that should be considered in
future face transplants.
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The working party reports estimated that 10% of facial allografts
could fail as a result of acute rejection2 and that, based on the hand
transplant experience, episodes of acute rejection may be
a common occurrence. To date, loss of a graft due to acute rejection
has not been reported. As predicted, episodes of acute rejection
have been frequent, occurring in almost all face transplants with
follow-up reports and have been successfully controlled by
increasing systemic immunosuppression (Table 3).1,13,17,18,21e24
Theworking party reports predicted that chronic rejection could
affect 30e50% of facial allografts at ﬁve years.3 Other teams were
unable to quantify the risk of chronic rejection,4,5 but raised
concern over its potential effect on function of the allograft. The
recipient of the ﬁrst facial allograft is now in her ﬁfth year following
transplantation. An MRI scan performed at ﬁve years has shown no
difference between the native and grafted soft tissues, with normal
appearance of the vasculature.25 Furthermore, there has been no
clinical or histological evidence of chronic rejection in her or any
other recipient. Currently over 70 composite tissue hand trans-
plants have been performed and there has been one reported loss of
a graft due to underlying intimal hyperplasia in the arteries, which
may have resulted from chronic rejection.29 It, therefore, seems
that chronic rejection has had less of an impact than expected so far
in composite tissue allotransplantation. Whilst the functional,
aesthetic and psychological consequences of chronic rejection in
facial transplantation have been modelled,30 long-term follow-up
of recipients is required to determine the clinical outcomes of this
process.
The importance of tissue matching in facial transplantation
could not be determined when the working party reports were
written and still remains unclear. Episodes of rejection have been
observed, despite extents of donor/recipient HLA matching. In
addition, the number of acute rejection episodes observed has not
correlated with HLA matching.16,18,22,24 Long-term outcomes of the
initial face transplants will help determine the signiﬁcance of his-
tocompatability matching, inevitably inﬂuencing the future selec-
tion of recipients and donors.
As expected, immunosuppression used in facial transplantation
has been similar to that used in solid organ transplantation and
hand transplants. Corticosteroids, tacrolimus and mycophenolate
mofetil have been used in all patients with detailed reports
(Table 3). Treatment with bone marrow infusion, thymoglobulin,
anti-IL2 receptor antibodies, X-ray irradiation and phototherapy
have varied between centres.
Adverse effects of immunosuppression include drug toxicity,
opportunistic infections and malignancies.31 The most serious of
these side effects may result in conditions that shorten the life of
the recipient. Risks posed to face transplant recipients by immu-
nosuppressant therapy had, thus, historically been the subject of
ethical debate.8,31 Early reports predicted that the majority of face
transplant patients could expect to experience immunosuppres-
sant related side effects.3,4 Follow-up of face transplants performed
to date have described immunosuppressant side effects from drug
toxicity and opportunistic infections, including impaired renal
function, thrombotic microangiopathy, diabetes mellitus, cyto-
megalovirus and herpes simplex virus infection (Table 3).1,17,21,23,24
These complications have almost all been successfully managed.
The sixth face transplant recipient developed multi-resistant
pseudomonas aeruginosa on post-operative day 15, affecting the
facial graft, requiring tapering of the immunosuppression and
surgical excision of the infected tissue.18 An EBV related post-
transplant B-cell lymphoma occurred in the second recipient of
the Lyon/Amiens group. This affected the liver, spleen, pancreas,
lungs and lymph nodes and was treated with rituximab, resultingin full remission.32 The Valencia patient developed a pseudo-
sarcomatous spindle-cell nodule at the base of the tongue on post-
operative month 11.33 This benign pseudotumour was removed
surgically and there have been no reports of recurrence.
There had been optimism that protocols to induce transplant
tolerance could be developed within the ﬁrst few years of the face
transplant programme.3 However, this was not considered likely. In
an attempt to induce transplant tolerance, bone marrow was
transplanted with the ﬁrst face transplant. Multiple assessments
during the 18-month period following transplantation demon-
strated haematopoietic microchimerism only on one occasion.
There have been two reported mortalities amongst the face
transplant recipients.34,35 The Chinese patient died 27 months
following his transplant. A post-mortem to conﬁrm the exact cause
of death was not performed. However, it is believed that he dis-
continued his immunosuppression and consequently developed
multi-organ failure.36 The second reported mortality was the sixth
recipient,35 who received a facial myocutaneous allograft with
concomitant bilateral below-elbow upper limb transplants. This
patient experienced a cardiac arrest due to tracheostomy obstruc-
tion.18 Following ﬁve weeks of intensive care therapy, the patient
died on day 65 post-operatively.18 This recipient developed areas of
skin necrosis, related to multi-resistant pseudomonas aeruginosa
infection, but several biopsies from the transplanted tissue were
negative for immune-mediated rejection.35
5. Psychological outcomes
Potential psychological issues, raised in the initial medical
literature on facial transplantation, included early post-operative
distress,11 communication difﬁculties,2,11 feelings of depersonali-
sation towards the new face and avoidance behaviours.11 In addi-
tion, it was thought that face transplant recipients might be prone
to anxiety or depression due to the large number of stressors
present such as the fear of graft viability or rejection, worry about
immunosuppressant side effects, feelings of personal responsibility
for the success of the graft linked to adherence of treatment
regimes, identity transfer and emotional responses towards the
donor.2,3,11
Identity transfer from donor to recipient had excited consider-
able lay interest, in part generated by the media. This was
mentioned as a potential risk in the working party reports of The
Royal College of Surgeons.2,3 However, this concern was not shared
by the scientiﬁc community involved in the development of facial
transplantation. Thus far, no concerns regarding identity transfer
have been reported amongst face transplant recipients.
Psychological outcomes in the fourth face transplant recipient
have been evaluated quantitatively.37 Measurable ratings of
depression, body image, quality of life and societal reintegration
showed improvements following facial transplantation. Scores
measuring psychological distress rose at three months post-
transplant, when the patient started socialising and then mark-
edly fell. However, a subsequent rise in psychological distress was
seen, which coincided with CMV infection. Measurement of teasing
revealed that the patient suffered less teasing and verbal abuse,
whilst receiving more positive afﬁrmations from observers after
the transplant.37 Anxiety and self-esteem scores remained constant
following the procedure.37 Lantieri et al have described improve-
ments in quality of life and appearance, measured quantitatively, in
their ﬁrst four recipients.18 In addition, two of these patients have
been able to return to employment.18,21
Although objective psychological assessment, using validated
measures, has not yet been reported amongst the other face
transplant recipients, favourable psychological outcomes have
been observed. The ﬁrst recipient of a face transplant was able to
Table 3
Immunological outcomes of facial transplantation.
Team HLA
Matches
Immunosuppression Rejection
episodes
Immunosuppression
complications
Devauchelle/
Dubernard (1)
5/6 Induction e antithymocyte
globulin, tacrolimus, MMF,
prednisolone.
Maintenance e tacrolimus,
MMF, prednisolone. Bone
marrow infusion d4,11.
2 (d18, 214) Decline in renal function
HSV lip infection
Molluscum contagiosum
Thrombotic microangiopathy
Hypertriglyceridaemia
Hypertension
Bilateral bacterial pneumonia
Mild cholangitis
Guo 3/6 Induction e prednisolone,
MMF, tacrolimus,
methylprednisolone,
anti-IL-2 receptor MAb,
Maintenance e tacrolimus,
MMF, prednisolone
(stopped at 22 mo)
3 (mo3, 5, 17) Hyperglycaemia (d3)
Diabetes mellitus (mo3)
Lantieri 3/6 Induction e antithymocyte
globulin, tacrolimus, MMF,
prednisolone
Maintenance e tacrolimus,
MMF, prednisolone,
2 (d28, 64) Steroid induced confusion
post-op
CMV viraemia (d64)
Siemionow 2/6 Induction e antithymocyte globulin,
methylprednisolone.
Maintenance e tacrolimus, MMF,
prednisolone
1 (d47) CMV infection at 7 months
Transient leukopaenia
(wk2, mo6)
Lantieri (2) 1/6 Induction e antithymocyte globulin,
tacrolimus, MMF, prednisolone
Maintenance e tacrolimus,
MMF, prednisolone
1 (d0) Pseudomonas aeruginosa
pneumonia (d2)
Lantieri (3) 2/6 Induction e antithymocyte
globulin, tacrolimus, MMF,
prednisolone
Maintenance e tacrolimus,
MMF, prednisolone
0 Multiresistant pseudomonas
aeruginosa infection (d12-65)
Pomahac (1) 3/6 Induction e antithymocyte
globulin, methylprednisolone, MMF
Maintenance e MMF, tacrolimus,
steroid taper
1 (d17) Post-transplant diabetes
Steroid bolus treatments
given d74, 107. 3 courses
of topical treatment given.
Persistent facial redness
attributed to rosacea
transferred from donor.
Cavadas 0/6 Induction e basiliximab,
tacrolimus, MMF, corticosteroids
Maintenance e Tacrolimus,
mycophenolate mofetil, prednisolone
2 (d14, 350) Pseudosarcomatous
spindle-cell nodule at
base of tongue (mo11)
Lantieri (4) 2/6 Induction e antithymocyte
globulin, tacrolimus, MMF,
prednisolone
Maintenance e tacrolimus,
MMF, prednisolone
1 (d5) HSV 1 infection of lips (d3-10)
Devauchelle/
Dubernard
(2)
1/6 Induction e antithymocyte
globulin, tacrolimus,
prednisolone, MMF
Maintenance e tacrolimus,
prednisolone
5 (d41, 103,
mo6, 16, 18)
Staphlococcus aureus and
Candida glabrata in post-op phase.
HSV 1 infection of graft
(d6, 86, 160, 226, mo16)
EBV related post-transplant
B-cell lymphoma.(mo5)
Gomez Cia Not yet reported Induction e Basiliximab, tacrolimus,
methylprednisolone
Mainenance e Not yet reported
Not yet reported Rhabdomyolysis (d1) with
renal impairment (but not
attributed to immunosuppression)
Barret 0/6 Induction e antithymocyte
globulin, prednisolone
Maintenance e tacrolimus,
MMF, prednisolone
3 (d3, 28, 75) No infectious complications
reported at 4mo.
Lantieri (5) Not yet reported Not yet reported Not yet reported Not yet reported
Pomahac (2) Not yet reported Not yet reported Not yet reported Not yet reported
(continued on next page)
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Table 3 (continued )
Team HLA
Matches
Immunosuppression Rejection
episodes
Immunosuppression
complications
Pomahac (3) Not yet reported Not yet reported Not yet reported Not yet reported
Lantieri (6) Not yet reported Not yet reported Not yet reported Not yet reported
Lantieri (7) Not yet reported Not yet reported Not yet reported Not yet reported
Pomahac (4) Not yet reported Not yet reported Not yet reported Not yet reported
Abbreviations: HLA e human leukocyte antigen, MMF e mycophenolate mofetil, MAb e monoclonal antibody, CMV - cytomegalovirus.
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REVIEWface the outside world and start socialising by the twelfth post-
operative week,1 with psychological acceptance of the graft
correlated to return of expressiveness. Eighteen months following
transplantation, this patient was reported to be able to walk in the
street and meet new people without any problems.22 Despite the
poor outcome eventually observed in the second face transplant,
the patient accepted his new face easily.17 No signiﬁcant psycho-
logical issues were reported at one year in the seventh recipient of
a face transplant.24 This patient returned home ﬁve weeks post-
operatively and was able to re-integrate into his community
with enhanced social capacity. Favourable psychological outcomes
have also been reported in two of the Spanish face transplant
recipients.13 Whilst publications in the medical literature are
awaited, the last three face transplant recipients in Boston have
been able to face the media and have reported encouraging
psychological beneﬁts.38
6. Discussion
Composite tissue allotransplantation of the face offers some
clear advantages over other reconstructive methods. Unlike ﬂaps
and grafts, facial transplantation upholds the Gillies principle of
“replacing like with like”. The intricate and visible structures of the
face mean that transplantation can yield better functional and
aesthetic results than reconstruction using conventional methods.
However, facial transplantation remains controversial. Unlike
cardiac, lung and liver transplants, facial allografts are not life-
saving. Therefore, the decision for every patient considering this
procedure is whether the life-enhancing beneﬁts merit the surgical,
immunological and psychological risks.
The initial success of facial transplantation is testament to the
careful approach taken by the face transplant teams and the
guidance set out by the American Society of Plastic Surgery39 and
the Royal College of Surgeons of England.3 Thus far, surgical,
functional and aesthetic, immunological and psychological
outcomes have been very encouraging. Facial transplantation has
conferred reduction in chronic pain levels and improvements to
important functions such as smiling, smelling, eating, drinking and
speaking. The impact of these changes on quality of life has been
considerable and resulted in the reintegration of these patients into
the outside world, social networks and even the workplace.
Despite the remarkable surgical success to date, continued
reﬁnement of technique is necessary to avoid the extensive blood
loss seen in face transplants thus far.17e19 Future teams must also
have clear recovery plans in the event of failure, as described by
Butler et al.40
The immunsuppression related side-effects observed in face
transplant recipients to date have included malignancy and organ
toxicity. This has highlighted that facial transplantation should be
performed by an experienced multi-disciplinary team, including
transplant immunologists. Based on the current experience,
recipients should be matched for EBV status and given prophy-
laxis for opportunistic infections. The occurrence of these
complications has also emphasised that facial transplantationshould be limited to patients with the most severe aesthetic and
functional deﬁcits, for whom reconstruction with autologous
tissue is not feasible.
Rejection is probably implicated in the mortality of the Chinese
patient.17 A similar problem was encountered at the start of the
hand transplant programme, as the ﬁrst allograft was rejected at 27
months.41 These experiences demonstrate the importance of
adherence to immunosuppressive regimens, which should be
provided by the institutions undertaking the procedure. Thus,
robust patient selection and support is the key predictor of
successful outcome. Future face transplant teams must meticu-
lously complete a rigorous patient-selection process.42 In doing so,
they can identify patients with realistic expectations who can
comply with follow-up.
The second mortality following facial transplantation was in
a patient that received concomitant facial and below-elbow
composite tissue allografts.35 The most recent facial transplant,
performed in Boston also included concomitant bilateral hand
transplants, which were subsequently removed.38 It is important
to note that failure of the hand transplants in this patient has not
worsened their pre-operative status. The Boston team have also
announced that this patient may be considered again for further
hand transplants.38 Siemionow et al have addressed the issues in
concomitant face and hand transplantation.43 Due to the
complexity of concomitant transplantation and the limited
experience of facial transplants, they have recommended staged
reconstruction as the best option for the time being. Individual
teams will need to evaluate the beneﬁts and risks of concomitant
composite tissue allotransplantation before deciding on treat-
ment options.
7. Conclusions
The face transplant debate is similar to that which accompanied
the development of solid organ transplantation. Renal and liver
transplants are now well- accepted treatment options. However,
the initial experience of both of these transplant programmes
brought difﬁcult challenges and frequent patient mortality.44e46 By
comparison, the early face transplant experience generally has
been far more positive than predicted, although it is important to
acknowledge that facial transplantation is not a life-saving
intervention.
The early face transplant experience has demonstrated its
feasibility as a reconstructive option. However, it remains an
experimental procedure, which requires an experienced multi-
disciplinary team. Dissemination of outcomes has allowed prog-
ress to be made, with teams performingmore extensive procedures
and considering a wider range of patients,47 including an HIV
positive recipient.33 However, important information on functional
outcomes and complications still remain outstanding. Face trans-
plant teams should be encouraged to be transparent about their
experiences. With this information facial transplantation may
eventually become a ﬁrst-line reconstructive option for patients
with severe facial disﬁgurements.
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